Suppr超能文献

法布里病R363C变异体的表型变异性与性别悖论

Phenotypic variability and the gender paradox in the R363C variant of Fabry disease.

作者信息

Leslie Alison C, Jarnes Jeanine, Ahmed Alia, Shrestha Sofia, Wang Jeffrey, Whitley Chester B, Pillai Nishitha R

机构信息

University of Minnesota Medical School Minneapolis Minnesota USA.

Division of General Internal Medicine Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA.

出版信息

JIMD Rep. 2025 Jan 16;66(1):e12466. doi: 10.1002/jmd2.12466. eCollection 2025 Jan.

Abstract

Fabry disease is an X-linked lysosomal disease caused by variants in the gene. Although Fabry disease is X-linked, gene variants in females can exhibit a wide range of symptoms, challenging the traditional view of Fabry as an X-linked recessive disease. A family is presented here with a 36-year-old female who is symptomatic with chronic kidney disease and her oligosymptomatic 70-year-old father, both of whom have a heterozygous and hemizygous GLA pathogenic variant, respectively, c.1087C>T (p.R363C). Interestingly, the proband's Lyso-GL-3 levels were lower than her father's despite her more severe clinical presentation. The discordance between clinical severity and Lyso-GL-3 levels, particularly in the context of migalastat therapy, raises questions about the appropriate interpretation and use of this biomarker. The earlier and more severe symptom onset in the female proband suggests the potential role of genetic modifiers or other factors influencing disease expression. This report underscores the complexity of Fabry disease phenotypes and the limitations of current biomarkers in predicting disease severity, particularly in females. The observed paradox between clinical symptoms and biomarker levels suggests the need for a deeper understanding of the underlying mechanisms driving phenotypic variability in Fabry disease.

摘要

法布里病是一种由该基因变异引起的X连锁溶酶体疾病。尽管法布里病是X连锁的,但女性中的该基因变异可表现出广泛的症状,这对法布里病作为一种X连锁隐性疾病的传统观点提出了挑战。本文介绍了一个家庭,其中一名36岁有慢性肾病症状的女性及其症状较少的70岁父亲,两人分别有一个杂合和半合子的GLA致病变异,即c.1087C>T(p.R363C)。有趣的是,先证者的溶酶体GL-3水平低于她父亲,尽管她的临床表现更严重。临床严重程度与溶酶体GL-3水平之间的不一致,特别是在米加司他治疗的背景下,引发了关于该生物标志物的恰当解读和应用的问题。女性先证者更早且更严重的症状发作表明遗传修饰因子或其他影响疾病表现的因素可能发挥了作用。本报告强调了法布里病表型的复杂性以及当前生物标志物在预测疾病严重程度方面的局限性,尤其是在女性患者中。临床症状与生物标志物水平之间观察到的矛盾表明需要更深入地了解驱动法布里病表型变异的潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8fa/11736146/2b592df90c0c/JMD2-66-e12466-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验